JP2020506962A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506962A5
JP2020506962A5 JP2019560066A JP2019560066A JP2020506962A5 JP 2020506962 A5 JP2020506962 A5 JP 2020506962A5 JP 2019560066 A JP2019560066 A JP 2019560066A JP 2019560066 A JP2019560066 A JP 2019560066A JP 2020506962 A5 JP2020506962 A5 JP 2020506962A5
Authority
JP
Japan
Prior art keywords
seq
hla
antibody
neoantigen
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019560066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506962A (ja
JP7303750B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/015086 external-priority patent/WO2018140525A1/en
Publication of JP2020506962A publication Critical patent/JP2020506962A/ja
Publication of JP2020506962A5 publication Critical patent/JP2020506962A5/ja
Priority to JP2023102868A priority Critical patent/JP2023134503A/ja
Application granted granted Critical
Publication of JP7303750B2 publication Critical patent/JP7303750B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019560066A 2017-01-24 2018-01-24 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 Active JP7303750B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023102868A JP2023134503A (ja) 2017-01-24 2023-06-22 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762449954P 2017-01-24 2017-01-24
US62/449,954 2017-01-24
US201762460585P 2017-02-17 2017-02-17
US62/460,585 2017-02-17
PCT/US2018/015086 WO2018140525A1 (en) 2017-01-24 2018-01-24 Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023102868A Division JP2023134503A (ja) 2017-01-24 2023-06-22 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物

Publications (3)

Publication Number Publication Date
JP2020506962A JP2020506962A (ja) 2020-03-05
JP2020506962A5 true JP2020506962A5 (https=) 2021-03-04
JP7303750B2 JP7303750B2 (ja) 2023-07-05

Family

ID=62979691

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019560066A Active JP7303750B2 (ja) 2017-01-24 2018-01-24 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物
JP2023102868A Pending JP2023134503A (ja) 2017-01-24 2023-06-22 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023102868A Pending JP2023134503A (ja) 2017-01-24 2023-06-22 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物

Country Status (5)

Country Link
US (1) US20190071502A1 (https=)
EP (1) EP3573997A4 (https=)
JP (2) JP7303750B2 (https=)
CN (1) CN110809580A (https=)
WO (1) WO2018140525A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
KR102643923B1 (ko) 2014-12-23 2024-03-05 이매틱스 바이오테크놀로지스 게엠베하 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
AU2019309948A1 (en) * 2018-07-23 2021-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
CN113366312A (zh) * 2018-11-01 2021-09-07 伯克利之光生命科技公司 在微流体环境中测定生物细胞的方法
JP2022538494A (ja) * 2019-07-05 2022-09-02 インテレクソン ゲゼルシャフト ミット ベシュレンクテル ハフツング 医療と診断におけるｈｌａ－ｈ
CN110491450B (zh) * 2019-08-23 2023-05-16 深圳市新合生物医疗科技有限公司 肿瘤新生抗原预测平台及其应用
AU2020369092A1 (en) * 2019-10-25 2022-05-12 Intellexon Gmbh HLA-H, HLA-J, HLA-L, HLA-V and HLA-Y as therapeutic and diagnostic targets
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981997B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US20230322953A1 (en) * 2020-06-30 2023-10-12 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
WO2022002038A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 免疫细胞衔接器多特异性结合蛋白及其制备和应用
CN115667316A (zh) * 2020-06-30 2023-01-31 和铂医药(上海)有限责任公司 Fab-HCAb结构的结合蛋白
US20250051454A1 (en) * 2020-09-15 2025-02-13 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof
CA3229447A1 (en) * 2021-08-20 2023-02-23 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof
JPWO2023112965A1 (https=) * 2021-12-15 2023-06-22
EP4598569A1 (en) * 2022-10-05 2025-08-13 Tscan Therapeutics, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
WO2024084091A1 (en) * 2022-10-21 2024-04-25 Medizinische Universität Wien Materials and methods to treat epstein-barr virus (ebv) and ebv-induced diseases
WO2025064029A1 (en) * 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibody molecules binding to a peptide-mhc interface
GB202316281D0 (en) * 2023-10-24 2023-12-06 Replay Holdings Inc Methods and compositions for modulating immune cell activity in cellular therapy
WO2026024596A1 (en) * 2024-07-22 2026-01-29 The Children's Hospital Of Philadelphia Methods of stimulating an immune response

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
WO1999018129A1 (en) * 1997-10-02 1999-04-15 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
DE60142615D1 (de) * 2000-04-28 2010-09-02 Mannkind Corp Epitop-synchronisierung in antigen präsentierenden zellen
WO2008103471A2 (en) 2007-02-23 2008-08-28 The Trustees Of Columbia University In The City Of New York Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease
CA2682093A1 (en) * 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
GB201003198D0 (en) * 2010-02-25 2010-04-14 Arab Biotechnology Company Compositions and methods for the treatment of cancer
CA2805564A1 (en) * 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
US9290541B2 (en) * 2011-11-18 2016-03-22 Board Of Regents, The University Of Texas System TCL1 peptides for immunotherapy
US10656156B2 (en) * 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
TWI853985B (zh) * 2013-12-04 2024-09-01 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
CN107922471A (zh) * 2015-06-24 2018-04-17 优瑞科生物技术公司 靶向ny‑eso‑1肽/mhc复合物的构建体及其用途
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés

Similar Documents

Publication Publication Date Title
JP2020506962A5 (https=)
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
MY207205A (en) Cd3 antibody and pharmaceutical use thereof
JP2022048153A5 (https=)
NZ726520A (en) Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
JP2018524987A5 (https=)
JP2017537972A5 (https=)
JP2017535292A5 (https=)
JP2009526823A5 (https=)
CR20200014A (es) Molécula de polipéptido con especificidad dual mejorada
JO3744B1 (ar) مواد ربط لـpd1 و/ أو lag3
MX2020010460A (es) Receptores de células t, y células diseñadas que expresan los mismos.
WO2016077840A3 (en) Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
EP4424376A3 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
JP2016500251A5 (https=)
MX2020009475A (es) Inmunoterapia con celulas car de anticuerpos biespecificos.
JP2018504143A5 (https=)
JP2020516305A5 (https=)
JP2019525898A5 (https=)
JP2015083010A5 (https=)
EP4234581A3 (en) Therapeutic antibodies and their uses
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
JP2018509163A5 (https=)